Choice of Antihypertensive agent According to Stage of Hypertension
Written By : Dr. Nandita Mohan
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2022-08-02 03:45 GMT | Update On 2023-10-11 09:36 GMT
Advertisement
The present study in the Journal of the associations of Physicians of India (JAPI) intended to estimate the comorbidities and risk factors among patients with hypertension in India. The study evaluated the current practice of hypertension management and the choice of therapy based on hypertension grade, risk factors, and comorbidities.
The study used Electronic medical record data of Indian adult hypertensive patients) who had two blood pressure readings.
A total of 1,00,075 patients, were included in the study. The proportion of patients with a BMI of less than 25 was 8.1%, 25-29.9 was 11.9%, and greater than 30 Kg/m2 was 8.8%. The mean BP of patients with hypertension was: grade, grade II, and grade III.
Mean low-density lipoprotein, serum creatinine, and mean HbA1c levels were highest among patients with grade III hypertension. Commonly observed comorbidities were type 2 diabetes mellitus, dyslipidemia, and chronic kidney disease. Top concomitant medications included anti-diabetic therapies, drugs for dyslipidemia, and anti-platelet therapies.
Researchers, therefore, concluded that the most prescribed Anti Hypertensive Drug monotherapies were angiotensin receptor II blockers (ARBs) and calcium channel blockers (CCBs) and the most prescribed combination therapies were angiotensin receptor II blockers + diuretics and angiotensin receptor II blockers + calcium channel blockers. Telmisartan and amlodipine+telmisartan for patients with comorbid Type 2 Diabetes Mellitus or dyslipidemia and metoprolol for those with coronary artery disease were the commonly prescribed Anti Hypertensive Drugs.
Reference: Md.Yunus Khan, Sucheta Pandit, Jamshed Dalal "Retrospective, Observational Study to Determine the Choice of Antihypertensive agent According to Stage of Hypertension, Risk factors and Co-morbidities in Real World Setting in India: A Report of Baseline Data", volume issue: 69; JAPI.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.